USFDA complete audit of Granules Pharmaceuticals with 3 observations

There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

174
Audit, Inspection, Documents , medicine
Picture: Pixabay

Last Updated on March 17, 2022 by The Health Master

Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of Hyderabad based Granules India Ltd. located in Chantilly, Virginia, US, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA).

“We are glad to have completed yet another audit after successfully addressing minor observations.

This is the sixth successful USFDA audit for this facility,” Priyanka Chigurupati, Executive Director, GPI, said in a release on Monday. 

The GPI facility was inspected by the US FDA during January 24-28, 2022, for two of its product applications filed.

There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg

Govt releases draft National Medical Device Policy 2022

Deadline extended for proposals under PLI scheme for Bulk Drugs

USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets

Orders to close these 5 Pharmaceutical units

USFDA inspections back in full swing for Pharma Companies

Drug recall: Macleods recalls products for these manufacturing issues

NITI Aayog to expand ‘Medicines from the Sky’ project

Make Pharma Companies liable for bribing doctors: PIL

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner